JP5785189B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP5785189B2 JP5785189B2 JP2012544681A JP2012544681A JP5785189B2 JP 5785189 B2 JP5785189 B2 JP 5785189B2 JP 2012544681 A JP2012544681 A JP 2012544681A JP 2012544681 A JP2012544681 A JP 2012544681A JP 5785189 B2 JP5785189 B2 JP 5785189B2
- Authority
- JP
- Japan
- Prior art keywords
- cap
- mmol
- calculated
- mixture
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COCC(COC)[C@@](C(N([C@](C1)C1C1)[C@@]1c([n]1)nc(-c(cc2)ccc2-c(cc2)ccc2-c2c(*)[n]c([C@](C[C@@]3[C@@]4C3)N4C([C@](C(COC)COC)NC(OC)=O)=O)n2)c1Cl)=O)NC(OC)=O Chemical compound COCC(COC)[C@@](C(N([C@](C1)C1C1)[C@@]1c([n]1)nc(-c(cc2)ccc2-c(cc2)ccc2-c2c(*)[n]c([C@](C[C@@]3[C@@]4C3)N4C([C@](C(COC)COC)NC(OC)=O)=O)n2)c1Cl)=O)NC(OC)=O 0.000 description 6
- VXBGUTXPLXWWPT-UBHUBRDASA-N CC(C)(C)OC(N(C(C1)C1C1)[C@@H]1c1nc(-c(cc2)ccc2Br)c(C(N)=O)[nH]1)=O Chemical compound CC(C)(C)OC(N(C(C1)C1C1)[C@@H]1c1nc(-c(cc2)ccc2Br)c(C(N)=O)[nH]1)=O VXBGUTXPLXWWPT-UBHUBRDASA-N 0.000 description 1
- WPMTYMFNINZZHE-KYJUHHDHSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](CCC3)N3C(OC(C)(C)C)=O)n2)c[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](CCC3)N3C(OC(C)(C)C)=O)n2)c[nH]1)=O WPMTYMFNINZZHE-KYJUHHDHSA-N 0.000 description 1
- BONHKCQIMVZXBV-UHFFFAOYSA-N CC(C)(C1)OCCC1O Chemical compound CC(C)(C1)OCCC1O BONHKCQIMVZXBV-UHFFFAOYSA-N 0.000 description 1
- SIGJBDNBLCTRPL-SCSAIBSYSA-N CC(C)([C@@H](C(O)=O)NC(OC)=O)O Chemical compound CC(C)([C@@H](C(O)=O)NC(OC)=O)O SIGJBDNBLCTRPL-SCSAIBSYSA-N 0.000 description 1
- SBZWMDYQTWCQEM-UHFFFAOYSA-N CC(C)S(C1)C1(C(O)=O)N(C)Cc1ccccc1 Chemical compound CC(C)S(C1)C1(C(O)=O)N(C)Cc1ccccc1 SBZWMDYQTWCQEM-UHFFFAOYSA-N 0.000 description 1
- BVXZCLYUTLLMMV-LVTLXNKHSA-N CC(C)[C@@H](C(N(C(C1)[C@H]1C1)[C@@H]1c([nH]1)nc(-c(cc2)ccc2-c(cc2)ccc2-c(nc([C@H](C[C@@H](C)[C@H]2C)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)c2Br)c1Br)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(C(C1)[C@H]1C1)[C@@H]1c([nH]1)nc(-c(cc2)ccc2-c(cc2)ccc2-c(nc([C@H](C[C@@H](C)[C@H]2C)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)c2Br)c1Br)=O)NC(OC)=O BVXZCLYUTLLMMV-LVTLXNKHSA-N 0.000 description 1
- CFTCPBQSPSMTHC-OYWXURRPSA-N CC(C)[C@@H](C(N(C(C1)[C@H]1C1)[C@@H]1c([nH]1)nc(-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](C[C@@H](C)[C@H]3C)N3C([C@H](C(C)C)NC(OC)=O)=O)n2)c1Br)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(C(C1)[C@H]1C1)[C@@H]1c([nH]1)nc(-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H](C[C@@H](C)[C@H]3C)N3C([C@H](C(C)C)NC(OC)=O)=O)n2)c1Br)=O)NC(OC)=O CFTCPBQSPSMTHC-OYWXURRPSA-N 0.000 description 1
- XJGSOSZKHBFLMD-YDPTYEFTSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c(nc([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)c2Br)c[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c(cc2)ccc2-c(cc2)ccc2-c(nc([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)c2Br)c[nH]1)=O)NC(OC)=O XJGSOSZKHBFLMD-YDPTYEFTSA-N 0.000 description 1
- KNVOHNNXFGZIOL-KRCBVYEFSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(Br)c(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)n2)c2Br)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(Br)c(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)n2)c2Br)[nH]1)=O)NC(OC)=O KNVOHNNXFGZIOL-KRCBVYEFSA-N 0.000 description 1
- UWMUVLUTQUSZLL-YDPTYEFTSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)n2)c2Cl)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)n2)c2Cl)[nH]1)=O)NC(OC)=O UWMUVLUTQUSZLL-YDPTYEFTSA-N 0.000 description 1
- IGXBTGPQVSIPHR-IOVMKHCPSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](CC[C@@H]2C)N2C([C@H](C(C)C)NC(OC)=O)=O)n2)c2Cl)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](CC[C@@H]2C)N2C([C@H](C(C)C)NC(OC)=O)=O)n2)c2Cl)[nH]1)=O)NC(OC)=O IGXBTGPQVSIPHR-IOVMKHCPSA-N 0.000 description 1
- CEFVHPDFGLDQKU-RXMQYKEDSA-N CC(C)[C@H](C(O)=O)NC(OC)=O Chemical compound CC(C)[C@H](C(O)=O)NC(OC)=O CEFVHPDFGLDQKU-RXMQYKEDSA-N 0.000 description 1
- PENRGQIXWPSYEI-PRJDIBJQSA-N CC(C1)([C@@]1(C(O)=O)NC)S Chemical compound CC(C1)([C@@]1(C(O)=O)NC)S PENRGQIXWPSYEI-PRJDIBJQSA-N 0.000 description 1
- UGKKHYXLOZRJLZ-QIIDTADFSA-N CCOC(C([C@H]1C[C@H](C)OCC1)NC(OC)=O)=O Chemical compound CCOC(C([C@H]1C[C@H](C)OCC1)NC(OC)=O)=O UGKKHYXLOZRJLZ-QIIDTADFSA-N 0.000 description 1
- GKJPVYMOQKBWCE-PBLYYEMPSA-N CC[C@@H](C(N([C@H](C1)[C@H]1C1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](C[C@@H]2[C@H]3C2)N3C([C@H](CC)NC(OC)=O)=O)n2)c2Cl)[nH]1)=O)NC(OC)=O Chemical compound CC[C@@H](C(N([C@H](C1)[C@H]1C1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c([nH]c([C@H](C[C@@H]2[C@H]3C2)N3C([C@H](CC)NC(OC)=O)=O)n2)c2Cl)[nH]1)=O)NC(OC)=O GKJPVYMOQKBWCE-PBLYYEMPSA-N 0.000 description 1
- WWTABXAXNXQPOH-UHNVWZDZSA-N CN(C[C@@H](C1)F)[C@@H]1C(O)=O Chemical compound CN(C[C@@H](C1)F)[C@@H]1C(O)=O WWTABXAXNXQPOH-UHNVWZDZSA-N 0.000 description 1
- VBQNMJLWFTYJQQ-PRZNWYJVSA-N COC(N[C@@H](C1(C2)C2OCCC1)C(O)=O)=O Chemical compound COC(N[C@@H](C1(C2)C2OCCC1)C(O)=O)=O VBQNMJLWFTYJQQ-PRZNWYJVSA-N 0.000 description 1
- SWBDIYBLPKMZTK-JTQLQIEISA-N COC(N[C@@H](CC(OCc1ccccc1)=O)C(O)=O)=O Chemical compound COC(N[C@@H](CC(OCc1ccccc1)=O)C(O)=O)=O SWBDIYBLPKMZTK-JTQLQIEISA-N 0.000 description 1
- UMTLWTRSWSUNMF-BQBZGAKWSA-N COC(N[C@@H]([C@@H]1COCCC1)C(O)=O)=O Chemical compound COC(N[C@@H]([C@@H]1COCCC1)C(O)=O)=O UMTLWTRSWSUNMF-BQBZGAKWSA-N 0.000 description 1
- GOJLQSAREKTKPT-QMMMGPOBSA-N COC(N[C@H](C(O)=O)c1ccccc1)=O Chemical compound COC(N[C@H](C(O)=O)c1ccccc1)=O GOJLQSAREKTKPT-QMMMGPOBSA-N 0.000 description 1
- UMTLWTRSWSUNMF-NKWVEPMBSA-N COC(N[C@H]([C@@H]1COCCC1)C(O)=O)=O Chemical compound COC(N[C@H]([C@@H]1COCCC1)C(O)=O)=O UMTLWTRSWSUNMF-NKWVEPMBSA-N 0.000 description 1
- UMTLWTRSWSUNMF-RNFRBKRXSA-N COC(N[C@H]([C@H]1COCCC1)C(O)=O)=O Chemical compound COC(N[C@H]([C@H]1COCCC1)C(O)=O)=O UMTLWTRSWSUNMF-RNFRBKRXSA-N 0.000 description 1
- RNGLTUBJVAAYNC-UHFFFAOYSA-N COCC(COC)=C(C(OC)=O)NC(OCc1ccccc1)=O Chemical compound COCC(COC)=C(C(OC)=O)NC(OCc1ccccc1)=O RNGLTUBJVAAYNC-UHFFFAOYSA-N 0.000 description 1
- NRQNEMBSIAIKFB-UHFFFAOYSA-N COc1c(ccnc2)c2ccc1 Chemical compound COc1c(ccnc2)c2ccc1 NRQNEMBSIAIKFB-UHFFFAOYSA-N 0.000 description 1
- OOIJOKDKOOJZJS-BYPYZUCNSA-N C[C@@H](C(O)=O)NC(N(C)C)=O Chemical compound C[C@@H](C(O)=O)NC(N(C)C)=O OOIJOKDKOOJZJS-BYPYZUCNSA-N 0.000 description 1
- YGYLYUIRSJSFJS-QMMMGPOBSA-N C[C@@H](C(OCc1ccccc1)=O)N Chemical compound C[C@@H](C(OCc1ccccc1)=O)N YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 1
- ZHPKAPJNEIKPGV-NTSWFWBYSA-N C[C@@H](C1)OCC[C@H]1O Chemical compound C[C@@H](C1)OCC[C@H]1O ZHPKAPJNEIKPGV-NTSWFWBYSA-N 0.000 description 1
- IYPROFJQMBEUAL-TVHWNXBMSA-N C[C@@H](CC[C@H]1c2nc(c(cc3)c(cc4)cc3-c(cc3)ccc3-c(nc([C@H](CC[C@@H]3C)N3C([C@H](C3CCOCC3)NC(OC)=O)=O)[nH]3)c3Cl)c4[nH]2)N1C([C@H](C1CCOCC1)NC(OC)=O)=O Chemical compound C[C@@H](CC[C@H]1c2nc(c(cc3)c(cc4)cc3-c(cc3)ccc3-c(nc([C@H](CC[C@@H]3C)N3C([C@H](C3CCOCC3)NC(OC)=O)=O)[nH]3)c3Cl)c4[nH]2)N1C([C@H](C1CCOCC1)NC(OC)=O)=O IYPROFJQMBEUAL-TVHWNXBMSA-N 0.000 description 1
- MXKSXPYZNXUHEZ-YUMQZZPRSA-N C[C@@H](C[C@H]1C(O)=O)CN1C(OC(C)(C)C)=O Chemical compound C[C@@H](C[C@H]1C(O)=O)CN1C(OC(C)(C)C)=O MXKSXPYZNXUHEZ-YUMQZZPRSA-N 0.000 description 1
- KNPQZTRBMLBDPI-HWZXHQHMSA-N C[C@@](C1)(C1NC(OC)=O)C(O)=O Chemical compound C[C@@](C1)(C1NC(OC)=O)C(O)=O KNPQZTRBMLBDPI-HWZXHQHMSA-N 0.000 description 1
- YCJBUCVYZRAFFS-SKTFMFINSA-N C[C@H](CC[C@H]1c2nc(-c(cc3)ccc3-c(cc3)ccc3-c(nc([C@H](C[C@@H]3C4C3)N4C([C@H]([C@@H]3COCCC3)NC(OC)=O)=O)[nH]3)c3Cl)c[nH]2)N1C([C@H]([C@@H]1COCCC1)NC(OC)=O)=O Chemical compound C[C@H](CC[C@H]1c2nc(-c(cc3)ccc3-c(cc3)ccc3-c(nc([C@H](C[C@@H]3C4C3)N4C([C@H]([C@@H]3COCCC3)NC(OC)=O)=O)[nH]3)c3Cl)c[nH]2)N1C([C@H]([C@@H]1COCCC1)NC(OC)=O)=O YCJBUCVYZRAFFS-SKTFMFINSA-N 0.000 description 1
- GMPFKMIKKNTTQL-RQXZFJOKSA-N C[C@H](C[C@H]1c([nH]2)nc(-c(cc3)ccc3-c(cc3)ccc3-c(nc([C@H](CC3[C@H]4C3)N4C([C@H](CCOC)NC(OC)=O)=O)[nH]3)c3Cl)c2Cl)[C@@H](C)N1C([C@H](CCOC)NC(OC)=O)=O Chemical compound C[C@H](C[C@H]1c([nH]2)nc(-c(cc3)ccc3-c(cc3)ccc3-c(nc([C@H](CC3[C@H]4C3)N4C([C@H](CCOC)NC(OC)=O)=O)[nH]3)c3Cl)c2Cl)[C@@H](C)N1C([C@H](CCOC)NC(OC)=O)=O GMPFKMIKKNTTQL-RQXZFJOKSA-N 0.000 description 1
- DSAKQIKWJCHIOK-VHDUKHEWSA-N C[C@H](C[C@H]1c2nc(-c(cc3)ccc3-c(cc3)ccc3-c(nc([C@H](C[C@@H]3C4C3)N4C([C@H](CCOC)NC(OC)=O)=O)[nH]3)c3Cl)c[nH]2)[C@@H](C)N1C([C@H](CCOC)NC(OC)=O)=O Chemical compound C[C@H](C[C@H]1c2nc(-c(cc3)ccc3-c(cc3)ccc3-c(nc([C@H](C[C@@H]3C4C3)N4C([C@H](CCOC)NC(OC)=O)=O)[nH]3)c3Cl)c[nH]2)[C@@H](C)N1C([C@H](CCOC)NC(OC)=O)=O DSAKQIKWJCHIOK-VHDUKHEWSA-N 0.000 description 1
- KYNKAUUXUQOZSQ-GBXIJSLDSA-N C[C@H]([C@@H](C(O)=O)N1)OC1=O Chemical compound C[C@H]([C@@H](C(O)=O)N1)OC1=O KYNKAUUXUQOZSQ-GBXIJSLDSA-N 0.000 description 1
- QEHITIGLOAVDMO-KYRMOSQESA-N C[C@H]([C@@H]1C[C@H]2c([nH]3)nc(-c(cc4)ccc4-c(cc4)cc(cc5)c4c4c5[nH]c([C@H](CC[C@@H]5C6C5)N6C([C@H](C5CCOCC5)NC(OC)=O)=O)n4)c3Cl)[C@H]1N2C(C(C1CCOCC1)NC(OC)=O)=O Chemical compound C[C@H]([C@@H]1C[C@H]2c([nH]3)nc(-c(cc4)ccc4-c(cc4)cc(cc5)c4c4c5[nH]c([C@H](CC[C@@H]5C6C5)N6C([C@H](C5CCOCC5)NC(OC)=O)=O)n4)c3Cl)[C@H]1N2C(C(C1CCOCC1)NC(OC)=O)=O QEHITIGLOAVDMO-KYRMOSQESA-N 0.000 description 1
- WMAAUCPXSRLRDY-BNNJRXDXSA-N Cc1c(-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H]3NC(C4)C4C3)n2)nc([C@H]2NC(C3)C3C2)[nH]1 Chemical compound Cc1c(-c(cc2)ccc2-c(cc2)ccc2-c2c[nH]c([C@H]3NC(C4)C4C3)n2)nc([C@H]2NC(C3)C3C2)[nH]1 WMAAUCPXSRLRDY-BNNJRXDXSA-N 0.000 description 1
- RFYCQJHCAPCSTA-UHFFFAOYSA-N OC(Cc1c(CCl)cccc1)=O Chemical compound OC(Cc1c(CCl)cccc1)=O RFYCQJHCAPCSTA-UHFFFAOYSA-N 0.000 description 1
- GOSVNXMOCBVLPW-UHFFFAOYSA-N OC(Cc1c(CN2CCOCC2)cccc1)=O Chemical compound OC(Cc1c(CN2CCOCC2)cccc1)=O GOSVNXMOCBVLPW-UHFFFAOYSA-N 0.000 description 1
- USHNXHNIVWSXTR-UHFFFAOYSA-N OC(c1nc(F)cc2ccccc12)=O Chemical compound OC(c1nc(F)cc2ccccc12)=O USHNXHNIVWSXTR-UHFFFAOYSA-N 0.000 description 1
- CSGTZGMKSPXFEQ-UHFFFAOYSA-N OC1CC(CC2)OC2C1 Chemical compound OC1CC(CC2)OC2C1 CSGTZGMKSPXFEQ-UHFFFAOYSA-N 0.000 description 1
- BMXGLUVWNGLWCQ-ZXFHETKHSA-N O[C@@H]1C[C@@H]2O[C@@H]2C1 Chemical compound O[C@@H]1C[C@@H]2O[C@@H]2C1 BMXGLUVWNGLWCQ-ZXFHETKHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28694209P | 2009-12-16 | 2009-12-16 | |
| US61/286,942 | 2009-12-16 | ||
| US12/957,512 US8377980B2 (en) | 2009-12-16 | 2010-12-01 | Hepatitis C virus inhibitors |
| US12/957,512 | 2010-12-01 | ||
| PCT/US2010/060077 WO2011075439A1 (en) | 2009-12-16 | 2010-12-13 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514359A JP2013514359A (ja) | 2013-04-25 |
| JP2013514359A5 JP2013514359A5 (enExample) | 2014-01-09 |
| JP5785189B2 true JP5785189B2 (ja) | 2015-09-24 |
Family
ID=43479603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544681A Expired - Fee Related JP5785189B2 (ja) | 2009-12-16 | 2010-12-13 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8377980B2 (enExample) |
| EP (1) | EP2513091B1 (enExample) |
| JP (1) | JP5785189B2 (enExample) |
| KR (1) | KR20120107991A (enExample) |
| CN (1) | CN102741242B (enExample) |
| AR (1) | AR079634A1 (enExample) |
| AU (1) | AU2010332034B2 (enExample) |
| BR (1) | BR112012014677A2 (enExample) |
| CA (1) | CA2784662A1 (enExample) |
| CL (1) | CL2012001637A1 (enExample) |
| CO (1) | CO6561788A2 (enExample) |
| EA (1) | EA020815B1 (enExample) |
| MA (1) | MA33806B1 (enExample) |
| MX (1) | MX2012006635A (enExample) |
| NZ (1) | NZ601220A (enExample) |
| PE (1) | PE20121479A1 (enExample) |
| PH (1) | PH12012500979A1 (enExample) |
| SG (1) | SG181700A1 (enExample) |
| TN (1) | TN2012000264A1 (enExample) |
| TW (1) | TWI487702B (enExample) |
| WO (1) | WO2011075439A1 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2411395B1 (en) | 2009-03-23 | 2013-05-29 | Glenmark Pharmaceuticals S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| NZ595410A (en) | 2009-03-27 | 2013-12-20 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2541571C2 (ru) * | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| AU2010249080A1 (en) | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| WO2010138790A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| UA118080C2 (uk) * | 2009-06-11 | 2018-11-26 | Еббві Айрленд Анлімітед Компані | Противірусні сполуки |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| JP2013515746A (ja) * | 2009-12-24 | 2013-05-09 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症の治療又は予防のための類似体 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2011224698A1 (en) | 2010-03-09 | 2012-11-01 | Merck Sharp & Dohme Corp. | Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8859595B2 (en) | 2010-08-26 | 2014-10-14 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis C virus |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012048421A1 (en) * | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| JP5891235B2 (ja) | 2010-11-04 | 2016-03-22 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルスの新規阻害剤 |
| AU2011328980B2 (en) * | 2010-11-17 | 2015-07-30 | Gilead Sciences, Inc. | Antiviral compounds |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| MX2014002171A (es) * | 2011-08-24 | 2014-04-25 | Glaxosmithkline Llc | Tratamientos de combinacion para hepatitis c. |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| EP2755982A4 (en) * | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| AU2012308295B2 (en) | 2011-09-16 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating HCV |
| KR20140091036A (ko) | 2011-11-03 | 2014-07-18 | 세라밴스 인코포레이티드 | 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제 |
| DK2907816T3 (en) | 2011-11-16 | 2018-09-24 | Gilead Pharmasset Llc | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
| JP6069492B2 (ja) | 2012-04-25 | 2017-02-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルス阻害剤 |
| SI2850075T1 (sl) | 2012-04-25 | 2017-06-30 | Theravance Biopharma R&D Ip, Llc | Piperazin-piperidinske spojine kot inhibitorji virusa hepatitisa C |
| US9079887B2 (en) * | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| JP6196678B2 (ja) * | 2012-10-24 | 2017-09-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| JP6333372B2 (ja) | 2013-07-09 | 2018-05-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
| WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| CN103450071A (zh) * | 2013-09-05 | 2013-12-18 | 南京工业大学 | 一种医药中间体2-氮杂双环[3.1.0]己烷-2,3-二碳酸叔丁酯的不对称合成方法 |
| EP3080104A1 (en) * | 2013-12-11 | 2016-10-19 | Bristol-Myers Squibb Company | 4,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN104860931A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 丙肝病毒抑制剂及其制药用途 |
| MX2016013434A (es) * | 2014-04-15 | 2017-03-03 | Cocrystal Pharma Inc | Inhibidores potentes y selectivos del virus de la hepatitis c. |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TWI703141B (zh) * | 2015-03-12 | 2020-09-01 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的化合物及其在藥物中的應用 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN113045480A (zh) * | 2019-12-27 | 2021-06-29 | 尚科生物医药（上海）有限公司 | 一种沙格列汀杂环中间体的差向异构体的制备方法 |
| CN112679407B (zh) * | 2021-03-17 | 2021-06-04 | 南京桦冠生物技术有限公司 | 一种手性5-取代脯氨酸类化合物的制备方法 |
| CN117321059A (zh) | 2021-05-21 | 2023-12-29 | 吉利德科学公司 | 用于治疗寨卡病毒感染的四环化合物 |
| US12037340B2 (en) | 2021-05-21 | 2024-07-16 | Gilead Sciences, Inc. | Pentacyclic derivatives as Zika virus inhibitors |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10889A (en) | 1854-05-09 | Machineey pok | ||
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| JPH08505854A (ja) | 1993-01-14 | 1996-06-25 | マガイニン ファーマシューティカルズ，インク． | 修飾された末端を有するアミノ酸及びペプチド |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003249977A1 (en) | 2002-07-05 | 2004-01-23 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| AU2003264038A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| JP4717457B2 (ja) | 2005-02-08 | 2011-07-06 | 株式会社島精機製作所 | 紡績糸の糸継ぎ方法および糸継ぎを含む編地 |
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| WO2007031791A1 (en) | 2005-09-16 | 2007-03-22 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
| RU2441869C2 (ru) | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| EP2038253A1 (en) | 2006-05-30 | 2009-03-25 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| ES2745411T3 (es) | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW200831084A (en) | 2006-11-21 | 2008-08-01 | Genelabs Tech Inc | Anti-viral compounds |
| CA2672737A1 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| PT2250163E (pt) | 2008-02-12 | 2012-06-01 | Bristol Myers Squibb Co | Inibidores do vírus da hepatite c |
| WO2009102694A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | Heterocyclic derivatives as hepatitis c virus inhibitors |
| BRPI0822323A2 (pt) * | 2008-02-13 | 2015-06-16 | Bristol Myers Squibb Co | Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| KR101784830B1 (ko) | 2008-12-03 | 2017-10-16 | 프레시디오 파마슈티칼스, 인코포레이티드 | Ｈｃｖ ｎｓ5ａ의 억제제 |
| BRPI0922364A2 (pt) | 2008-12-03 | 2017-08-29 | Presidio Pharmaceuticals Inc | Composto, composição farmacêutica e uso de um composto |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| EP2398474A4 (en) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| CN102427731B (zh) | 2009-02-27 | 2015-05-13 | 英安塔制药有限公司 | 丙型肝炎病毒抑制剂 |
| CA2756255A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| PE20120773A1 (es) | 2009-03-27 | 2012-07-19 | Presidio Pharmaceuticals Inc | Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2541571C2 (ru) | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| US8436036B2 (en) | 2009-04-24 | 2013-05-07 | Janssen R&D Ireland | Diaryl ethers |
| AU2010249080A1 (en) | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| WO2010138790A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UA118080C2 (uk) | 2009-06-11 | 2018-11-26 | Еббві Айрленд Анлімітед Компані | Противірусні сполуки |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| AU2010280711A1 (en) | 2009-08-07 | 2012-02-09 | Janssen Sciences Ireland Uc | Phenyl ethynyl derivatives as hepatitis C virus inhibitors |
| AU2010280712B2 (en) | 2009-08-07 | 2015-10-22 | Janssen Sciences Ireland Uc | Bis-benzimidazole derivatives as hepatitis C virus inhibitors |
| WO2011026920A1 (en) | 2009-09-03 | 2011-03-10 | Tibotec Pharmaceuticals | Bis-benzimidazole derivatives |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| AU2010325980B2 (en) | 2009-12-04 | 2016-04-07 | National Health Research Institutes | Proline derivatives |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
| CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| JP2013515746A (ja) | 2009-12-24 | 2013-05-09 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症の治療又は予防のための類似体 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
| JP2013518062A (ja) | 2010-01-28 | 2013-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
-
2010
- 2010-12-01 US US12/957,512 patent/US8377980B2/en active Active
- 2010-12-10 TW TW099143331A patent/TWI487702B/zh not_active IP Right Cessation
- 2010-12-13 PE PE2012000831A patent/PE20121479A1/es not_active Application Discontinuation
- 2010-12-13 CN CN201080062796.3A patent/CN102741242B/zh not_active Expired - Fee Related
- 2010-12-13 MX MX2012006635A patent/MX2012006635A/es active IP Right Grant
- 2010-12-13 PH PH1/2012/500979A patent/PH12012500979A1/en unknown
- 2010-12-13 EA EA201270656A patent/EA020815B1/ru not_active IP Right Cessation
- 2010-12-13 KR KR1020127018317A patent/KR20120107991A/ko not_active Withdrawn
- 2010-12-13 WO PCT/US2010/060077 patent/WO2011075439A1/en not_active Ceased
- 2010-12-13 SG SG2012043857A patent/SG181700A1/en unknown
- 2010-12-13 EP EP10796540.2A patent/EP2513091B1/en not_active Not-in-force
- 2010-12-13 BR BR112012014677A patent/BR112012014677A2/pt not_active IP Right Cessation
- 2010-12-13 JP JP2012544681A patent/JP5785189B2/ja not_active Expired - Fee Related
- 2010-12-13 NZ NZ601220A patent/NZ601220A/en not_active IP Right Cessation
- 2010-12-13 AU AU2010332034A patent/AU2010332034B2/en not_active Ceased
- 2010-12-13 CA CA2784662A patent/CA2784662A1/en not_active Abandoned
- 2010-12-16 AR ARP100104697A patent/AR079634A1/es unknown
-
2012
- 2012-05-25 TN TNP2012000264A patent/TN2012000264A1/en unknown
- 2012-06-06 MA MA34944A patent/MA33806B1/fr unknown
- 2012-06-15 CL CL2012001637A patent/CL2012001637A1/es unknown
- 2012-07-04 CO CO12111939A patent/CO6561788A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ601220A (en) | 2014-07-25 |
| CN102741242B (zh) | 2015-07-01 |
| PH12012500979A1 (en) | 2014-09-05 |
| SG181700A1 (en) | 2012-07-30 |
| PE20121479A1 (es) | 2012-11-07 |
| WO2011075439A1 (en) | 2011-06-23 |
| CA2784662A1 (en) | 2011-06-23 |
| US20110286961A1 (en) | 2011-11-24 |
| JP2013514359A (ja) | 2013-04-25 |
| EA201270656A1 (ru) | 2012-11-30 |
| AU2010332034A1 (en) | 2012-08-02 |
| AU2010332034B2 (en) | 2016-04-14 |
| TN2012000264A1 (en) | 2013-12-12 |
| MA33806B1 (fr) | 2012-12-03 |
| EP2513091A1 (en) | 2012-10-24 |
| AR079634A1 (es) | 2012-02-08 |
| EA020815B1 (ru) | 2015-01-30 |
| CN102741242A (zh) | 2012-10-17 |
| EP2513091B1 (en) | 2017-04-12 |
| CO6561788A2 (es) | 2012-11-15 |
| TW201130825A (en) | 2011-09-16 |
| BR112012014677A2 (pt) | 2015-09-15 |
| MX2012006635A (es) | 2012-06-21 |
| US8377980B2 (en) | 2013-02-19 |
| KR20120107991A (ko) | 2012-10-04 |
| CL2012001637A1 (es) | 2012-10-12 |
| TWI487702B (zh) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5785189B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5847284B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5558556B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612660B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5697679B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5632910B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5615352B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TWI475019B (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP5425815B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5805763B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5619289B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5596861B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2010527373A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| MX2013012870A (es) | Inhibidores del virus de la hepatitis c. | |
| US9561212B2 (en) | Hepatitis C virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150109 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150721 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150723 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5785189 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |